AIM: Results on determinants of benzodiazepine (BZD) use in general and inappropriate use were inconsistent and mostly univariate. The relative importance of sociodemographic, psychological and physical determinants has never been investigated in a comprehensive, multivariate model. METHODS: We included 429 BZD users and 2423 non-users from the Netherlands Study of Depression and Anxiety (NESDA) in order to investigate sociodemographic, psychological and physical determinants of BZD use and inappropriate use by logistic and linear regression analyses. RESULTS: BZDs were used by a considerable proportion of the 2852 NESDA participants (15.0%). BZD use was independently associated with older age, singleness, unemployment, treatment in secondary care, higher medical consumption (more severe) anxiety, depression (OR [95% CI]=1.95 [1.29, 2.93]), comorbidity, insomnia, SSRI (OR [95% CI]=2.05 [1.55, 2.70]), TCA and other antidepressant (OR [95% CI]=2.44 [1.64, 3.62]) use. Overall, BZD use was rarely in accordance with all guidelines, mainly because most users (82.5%) exceeded the recommended duration of safe use. Inappropriate use was independently associated with older age (β=0.130) and chronic illnesses (β=0.120). Higher scores on agreeableness were associated with less inappropriate use. CONCLUSIONS: Mentally or physically vulnerable subjects were most likely to use BZDs. The most vulnerable (i.e. the old and physically ill) BZD users were at highest risk of inappropriate BZD use. Without further evidence of the effectiveness of BZDs in long-term use, caution in initiating BZD prescriptions is recommended, particularly when patients are chronically ill and old, as those are most likely to display inappropriate use.
AIM: Results on determinants of benzodiazepine (BZD) use in general and inappropriate use were inconsistent and mostly univariate. The relative importance of sociodemographic, psychological and physical determinants has never been investigated in a comprehensive, multivariate model. METHODS: We included 429 BZD users and 2423 non-users from the Netherlands Study of Depression and Anxiety (NESDA) in order to investigate sociodemographic, psychological and physical determinants of BZD use and inappropriate use by logistic and linear regression analyses. RESULTS:BZDs were used by a considerable proportion of the 2852 NESDA participants (15.0%). BZD use was independently associated with older age, singleness, unemployment, treatment in secondary care, higher medical consumption (more severe) anxiety, depression (OR [95% CI]=1.95 [1.29, 2.93]), comorbidity, insomnia, SSRI (OR [95% CI]=2.05 [1.55, 2.70]), TCA and other antidepressant (OR [95% CI]=2.44 [1.64, 3.62]) use. Overall, BZD use was rarely in accordance with all guidelines, mainly because most users (82.5%) exceeded the recommended duration of safe use. Inappropriate use was independently associated with older age (β=0.130) and chronic illnesses (β=0.120). Higher scores on agreeableness were associated with less inappropriate use. CONCLUSIONS: Mentally or physically vulnerable subjects were most likely to use BZDs. The most vulnerable (i.e. the old and physically ill) BZD users were at highest risk of inappropriate BZD use. Without further evidence of the effectiveness of BZDs in long-term use, caution in initiating BZD prescriptions is recommended, particularly when patients are chronically ill and old, as those are most likely to display inappropriate use.
Authors: Geeske B Ten Wolde; Arie Dijkstra; Pepijn Van Empelen; Arie Knuistingh Neven; Frans G Zitman Journal: Addict Behav Date: 2008-02-20 Impact factor: 3.913
Authors: Leonie Manthey; Erik J Giltay; Tineke van Veen; Arie Knuistingh Neven; Sophie A Vreeburg; Brenda W J H Penninx; Frans G Zitman Journal: J Clin Psychopharmacol Date: 2010-04 Impact factor: 3.153
Authors: Douglas W Levine; Daniel F Kripke; Robert M Kaplan; Megan A Lewis; Michelle J Naughton; Deborah J Bowen; Sally A Shumaker Journal: Psychol Assess Date: 2003-06
Authors: Brenda W J H Penninx; Aartjan T F Beekman; Johannes H Smit; Frans G Zitman; Willem A Nolen; Philip Spinhoven; Pim Cuijpers; Peter J De Jong; Harm W J Van Marwijk; Willem J J Assendelft; Klaas Van Der Meer; Peter Verhaak; Michel Wensing; Ron De Graaf; Witte J Hoogendijk; Johan Ormel; Richard Van Dyck Journal: Int J Methods Psychiatr Res Date: 2008 Impact factor: 4.035
Authors: Joëlle M Hoebert; Patrick C Souverein; Aukje K Mantel-Teeuwisse; Hubert G M Leufkens; Liset van Dijk Journal: Ann Fam Med Date: 2012 Jan-Feb Impact factor: 5.166
Authors: Leonie Manthey; Fawzia van Loenen-Frösch; Erik J Giltay; Tineke van Veen; Klaske Glashouwer; Brenda W J H Penninx; Frans G Zitman Journal: Br J Clin Pharmacol Date: 2014-03 Impact factor: 4.335
Authors: Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk Journal: Aust N Z J Psychiatry Date: 2011-09 Impact factor: 5.744
Authors: Kristjan Linnet; Larus S Gudmundsson; Frida G Birgisdottir; Emil L Sigurdsson; Magnus Johannsson; Margret O Tomasdottir; Johann A Sigurdsson Journal: BMC Fam Pract Date: 2016-06-06 Impact factor: 2.497
Authors: Izabela Fulone; Silvio Barberato-Filho; Michele Félix dos Santos; Carolina de Lima Rossi; Gordon Guyatt; Luciane Cruz Lopes Journal: BMC Public Health Date: 2016-01-20 Impact factor: 3.295